<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790985</url>
  </required_header>
  <id_info>
    <org_study_id>LOA-04P</org_study_id>
    <nct_id>NCT00790985</nct_id>
  </id_info>
  <brief_title>Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee</brief_title>
  <official_title>Phase 3. Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare flavocoxid with naproxen for patients with moderate to severe osteoarthritis of
      the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficay of flavocoxid compared with naproxen in subjects with moderate-severe osteoarthritis
      of the knee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flavonoid mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nonsteroidal anti-inflammatory drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavocoxid</intervention_name>
    <description>medical food</description>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <other_name>limbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>antiinflammatory drug</description>
    <arm_group_label>naproxen</arm_group_label>
    <other_name>naprosyn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to read and understand informed consent and questionnaires in
             English.

          -  Adults of either gender age 35-75 years, in general good health.

          -  Established X-ray diagnosis of osteoarthritis of at least one knee.

          -  Taken NSAID including COX-2 inhibitor in full therapeutic dose for at least one month
             prior to screening.

          -  Able and will to discontinue OA medications until flare criteria met.

          -  BMI&lt;/= 45

          -  Subjects must rate target knee at least 5 out of 10 on discomfort VAS at baseline
             visit.

          -  Have an increase of at least 15mm on a 100mm pain VAS from screening to baseline
             visit.

          -  Must use acceptable birth control if female.

          -  Screening fecal occult must be negative.

          -  Able to attend all required visits

          -  Physical Therapy is allowed as long as the type and frequency remains unchanged for
             the duration of the study.

        Exclusion Criteria:

          -  Refusal to sign consent.

          -  Inability to attend all clinic visits

          -  Grade 0-1 K-L changes in both knees or grade 4 K-L changes in either knee on standing
             A/P radiograph

          -  Pregant or lactating women

          -  History of serious cardio-vascular disease.

          -  Recurrent arrythmias, except PAT, cardiomyopathy, MI within one year of screening.

          -  History of chronic esophageal, gastric or duodenal disease

          -  History of upper GI bleeding within the past 2 years.

          -  Any GI disorder associated with malabsorption

          -  Any musculo-skeletal or neurological condition that results in pain or gait
             disturbance that might confound evaluation of target knee.

          -  Uncontrolled Diabetes Mellitus

          -  History of bleeding disorder or concurrent use of coumadin or any agent used to reduce
             blood clotting or platelet adhesiveness.

          -  Concurrent use of any anti-arthritic medication, including corticosteroids regardless
             of the reason for use. (low dose aspirin for cardioprotection is allowed)

          -  History of chronic renal disease with creatinine &gt;2.0 or nephrotic syndrome with 24
             hour protein excretion &gt;1000mg.

          -  Intra-articular injection of any hyaluronic acid preparation in the target knee joint
             within 4 months of baseline visit.

          -  Intra-articular injection of a corticosteroid in the target knee joint within 2 months
             of the baseline visit.

          -  BMA&gt;45

          -  History of allergic reaction to flavonoid or flavan containg foods or products
             (example: red wine, colored fruits and vegetable, brazel nuts, tea, natto)

          -  History of allergy to aspirin, naproxen or other NSAID

          -  History of substance abuse including alcohol, or any psychiatric condition that may
             impair the subject's ability to comply with the study requirements.

          -  Any medical condition that, in the opinion of the investigator, might put the subject
             at undue risk or might interfere with the subject's ability to participate in the
             study.

          -  Participation in another clinical trial within 30 days or 7 half lives of the study
             agent, whichever is longer, of the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul H Caldron, DO, FACP</last_name>
    <role>Study Director</role>
    <affiliation>AmeRuss Clinical Trials LLC, USA</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 11, 2017</submitted>
    <returned>January 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

